Condition: Gastric Cancer · Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and safety of nivolumab and FOLFOX in combination with EXL01 as first-line treatment. After signing the informed consent form, and upon confirmation of the patient's eligibility, patients will be randomized in a 2:1 ratio to either the nivolumab and FOLFOX plus EXL01 arm (experimental) or the nivolumab and FOLFOX arm (control). In both arms, treatment will be given until PD, unacceptable toxicity or for a maximum of 24 months (52 cycles).
This description comes directly from the study's public registry record.
Marie-Line GARCIA LARNICOL, MD · +33 (01) 40 29 85 04 · marie-line.garcia-larnicol@gercor.com.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancerologie de L'Ouest Paul Papin | Angers, France | Not Yet Recruiting |
| Clinique Sainte Catherine | Avignon, France | Recruiting |
| Centre Hospitalier Universitaire Jean Minjoz | Besançon, France | Recruiting |
| Institut Bergonie | Bordeaux, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire Morvan | Brest, France | Not Yet Recruiting |
| Centre Francois Baclesse | Caen, France | Not Yet Recruiting |
| Centre Hospitalier de Cholet | Cholet, France | Recruiting |
| Centre Hospitalier Universitaire Clermont Ferrand - Site Estaing | Clermont-Ferrand, France | Not Yet Recruiting |
| Centre Hospitalier Henri Mondor | Créteil, France | Not Yet Recruiting |
| Centre Georges Francois Leclerc | Dijon, France | Recruiting |
| Centre Hospitalier Universitaire Grenoble Alpes - Site Nord - Hopital Michallon | La Tronche, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Lille | Lille, France | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06253611